Introduction
The last five years have witnessed an explosion of interest in the use of oligodeoxynucleotides (oligos) as sequencespecific inhibitors of genetic expression. Oligos are short segments of single stranded DNA, usually > 15 nucleotides in length, that can be synthesized with a predetermined sequence. If the base sequence of a gene, and therefore the corresponding mRNA is known, an oligo can be targeted that is 'anti', or complementary in sequence, to it. Because of the exquisite specificity of Watson-Crick base pairing, the oligo, theoretically, will be able to bind only to mRNA transcripts of the targeted gene, thus forming an RNA-DNA duplex. This process may block translation of the transcript through hybrid arrest of the translational machinery, or by induction of RNase H activity, which cleaves the RNA strand of an RNA-DNA duplex, thereby effectively preventing expression of that gene. If the target is a viral mRNA, the result may be to eliminate a viral protein and to block viral expression, without affecting the infected cell.
Thus, the potential for oligodeoxynucleotide-based therapy in treating viral infections is clearly enormous. However, the reduction to practice of the concepts described above is not entirely straightforward. The purpose of this short review will be to discuss the potential of oligos as antiviral therapeutic agents, while focusing on some of the practical difficulties in achieving this goal.
Antisense technology has been used successfully in many in vivo systems to inhibit gene expression (for a recent review see Stein, 1992) . However, 'normal', or phosphodiester (PO) oligos are sensitive to nuclease degradation and have very short half lives in serum. Several backbone modifications have been created to try to circumvent this problem (Fig. 1) . One of the most studied modifications is the substitution of a sulphur atom for one of the non-bridging oxygen atoms on the internuc1eotide phosphate. Phosphorothioate (PS) oligos retain the charge and solubility of PO oligos but are resistant to nucleases. Melting temperatures of mRNA(PS)DNA duplexes are somewhat depressed relative to those for PO oligos (Stein et sl., 1988) , but PS oligos, at low concentration, will elicit human RNAse H activity. However, at higher concentration, PS oligos will non-sequence specifically inhibit human RNAse H activity (Gao et aI., 1992) . The substitution of a single SUlphur for oxygen also introduces a centre of chirality at phosphorus: the sulphur atom may be oriented (in a duplex) either into, or out of, the major groove. Since the automatic synthesis produces a random mixture of diastereomers at each phosphorus, 2 2 7 diastereomers can be produced in each synthesis of a PS 28-mer. The biological significance of this chirality problem is, at present, not well understood. Furthermore, PS oligos tend to have very high binding constants for some proteins (Stein et aI., 1993) ,and may inhibit the function of certain critical enzymes, e.g. RNAse H, as mentioned above.
Other classes of oligos, substituted at phosphorus, have also been synthesized. Replacement of both non-bridging oxygens by sulphurs results in phosphorodlthioate (PS2) oligos. These compounds are no longer chiral at phosphorus, but tend not to form high-melting duplexes with their complements (Marshall et a/., 1992) . They also exhibit high binding constants for certain proteins. Two other backbone modifications, the uncharged methylphosphonates (Laurence et a/., 1991) , and the neutral or positive phosphoramidates (Agrawal et el., 1988) have also been synthesized and tested as antiviral agents.
Oligonucleotides were first reported to inhibit viral replication by Zamecnik and Stephenson (1978) who utilized a Rous Sarcoma Virus system. Since then, oligos of all the types mentioned above have been studied as antiviral agents. However, in many of the systems studied, the primary effects have been independent of the base sequence (Stein et aI., 1991) . It should always be kept in mind that oligos in general, and PS oligos in particular, are not only magic bullets in Ehrlich's sense, but chemical entities in their own right. This means that they will exhibit non sequence-specific effects and toxicities as do all other drugs. This is particularly true in studies of the inhibitory properties of HIV-1 replication by PS oligos.
Inhibition of HIV-1 replication

Non sequence-specific effects
In 1987, Matsukura et aI., in a de novo infection assay system, observed that PS oligos were able to protect ATH8 cells from the cytopathic effects of HIV-1. Both PO and methylphosphonate oligos were ineffective. Surprisingly, among the PS oligos, the most active compounds were homopolymers of cytidine. The cytoprotective effect was dependent on the PS oligo length, with a 28-mer homopolymer of cytidine, SdC28, being the most potent protector, and a 5-mer, SdC5, being ineffective. Furthermore, SdC28 was able to block de novo DNA synthesis following HIV-1 infection. These results were confirmed and expanded by . The maximum cytoprotective effect occurred at a PS oligo concentration of 1-2 f.LM of a 21-28-mer virtually regardless of sequence; the only exceptions were homopolymers of dA. Mixed base sequences behaved identically to the homopolymers.
Agrawal et at. (1988) , found both sequence specific and non-specific effects when phosphorothioates and phosphoramidates were used to protect H9 and Molt3 cells from HIV infection. The compounds were compared by their ability to inhibit syncytium formation and by prevention of p24 gag production. At low concentrations, PS oligos directed against three separate mRNA sites were partially effective whereas control, nonsense, PS oligos were ineffective. However, at high concentrations (100f.Lg mr') all PS oligos were active. In addition, PS homopolymers were active inhibitors of HIV-1 replication in a concentration-dependent manner. Non sequence-specific inhibition of HIV-1 was also observed with PS2 oligos (Marshall et aI., 1992) . As with the PS oligos, in vitro. studies demonstrated a length dependent inhibition of the polymerase activity of HIV-1 RT by PS2 cytidine homopolymers. However, for any given chain length, the ID 50 for the dithioate was at least 30 fold less than for the monothioate: for example ID 50 (SdC15) = 1.8 f.LM, whereas ID 50 (S2dC14) = 62 nM. However, in a de novo infection assay S2dC14 had a cytoprotective effect approximately equal to that of SdC28; a cell loss of only 25-30% was observed with both oligos in the 0.5-3.0 f.LM concentration range.
A possible mechanism for the non sequence-specific effects of PS oligos was proposed by Majumdar et at. (1989) , who found that both OdC28 and SdC28 were linear competitive inhibitors of the DNA polymerase activity of HIV-1 reverse transcriptase with respect to the templateprimer, poly(rA)-oligodT. The K; of the PS oligo was two orders of magnitude (2.8nM vs. 560 nM) lower than the K; for OdC28. Inhibition of RT activity by the PS oligos was chain length dependent, and the Kj of SdC14 was approximately fivefold greater than that of SdC28 (2.8nM vs. 18 nM). The effect of SdC28 on other DNA polymerases was also evaluated. Cellular ex and 'Y polymerases as well as MuLV reverse transcriptase were sensitive to SdC28, with K;values similar to HIV-1 RT.However, pol 13 and Pol1 were not inhibited by the oligo.
For PS oligos to be effective non sequence-specific inhibitors of HIV-1 replication by inhibition of the viral RT, internalization of the oligos by the infected cell is required. However, the nature and efficiency of the cellular oligo internalization process is not well understood at present. PS oligos may also block HIV infection at the cell surface by preventing viral binding. , reported that SdC28 but not OdC28 could inhibit syncitium formation occurring when uninfected, C04 + CEM cells are incubated with chronically infected MOLT 3 cells. Moreover, as shown in an ELISA assay, and also by flow cytometry, SdC28 prevented the binding of purified HIV-1 envelope glycoprotein 120 (gp120) to immobilized C04 and to C04 + cells. SdC28 also inhibited binding of the C04 antibody Leu3a to C04+ cells, but eould not block OKT4 binding. OKT4 is an anti-C04 mAb that does not bind to C04 at the HIV-1 binding site. PS2 oligos were even more effective at inhibiting syncitium formation than the corresponding PS oligo.
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An additional non sequencp,;lpecific mechanism whereby PS oligos may interac!t' with HIV-1 involves binding to the v3 loop of gp120 (Stein et aI., 1993) . This interaction is not specific for oligos, as the v3 loop has already been shown to interact with several other polyanions, including dextran sulphate and pentosan polysulphate (Schols et aI., 1990; Lederman et aI., 1992) . In a solid phase ELISA assay, SdC28 (10 J.LM) completely blocked the binding of the v3 specific antibody mAb 9284, but not other anti gp120 mAbs, to immobilized gp120 (Stein et aI., 1993 ). An oligo length dependence was observed, with a considerable loss of blocking ability occurring below an 18mer. The PO oligos had lower binding constants than the PS oligos. A PO polythymidine 15-mer with an alkylating group covalently attached to the 5' terminus was used to modify rsgp120 in vitro. The value of K m = 4 J.LM. PS oligos were found to be competitors of alkylating-15-mer PO oligo binding to rsgp120. The binding constants of the PS oligos to rsgp20 were determined by use of the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . A length-dependent increase in binding constant was observed for PS oligos <18mer (Stein et al., 1993) . However, for PS oligos >18 bases in length, no further increase was seen, and SdC18, SdC21 and SdC28 all had almost identical binding affinities (c. 47 x 10-6 M -1
) . The data were consistent with the hypothesis that two oligo binding sites exist on the surface of the protein, and that only an oligo of > 15 bases in length is sufficiently long enough to bridge them.
Modification of PO and PS oligos by covalent attachment to a cholesteryl (Chol) moiety enhances their non sequence-specific ability to inhibit HIV-1 replication (Letsingeretal., 1989; Stein et sl., 1991) .A PS 10-merwith a 5' cholesteryl (Chol-SdC10) strongly blocked syncytium formation between infected 8E5 cells and SupT1 cells (10 50 = 7.5 f.1M). While this was not as effective as SdC28 (10 50 = 0.2 J.LM), the unmodified PS t t-mer (SdC11) was only slightly effective at 40 J.LM. Complete inhibition of RT activity by Chol-SdC10 was observed at 12 f.1M, whereas SdC11 had no inhibitory properties. The inhibition by Chol-SdC10 was non-competitive with template primer at low concentrations «5 J.LM) and competitive at high concentrations (6-12 J.LM). The origin of the non-competitive inhibition pathway is currently unclear.
Yet an additional non sequence-specific effect of PS oligos on HIV-1 replication may lie in their ability to inhibit protein kinase C (PKC) activity. This is particularly important in light of the observation by Fields et al. (1988) that inhibitors of PKC may block HIV-1-induced phosphorylation by PKC; this process appears to reduce HIV-1 infectivity. SdC28 is a potent in vitro inhibitor of PKC131 activity; the inhibition is competitive with respect to substrate (K; = 5.4 J.LM). Undoubtedly, there are also other processes (e.g. perhaps viral integration) that are essential for HIVinfectivity and replication that are inhibited in a non sequence-specific fashion by PS oligos.
With a view towards eventual clinical application of the non sequence-specific effects of PS oligos, Chou et al. (1991) studied the antiviral effects of combining SdC28 with other anti-HIV compound. These included AZT, interferon ex and dextran sulphate. Levels of p24 production and RT activity were examined. The combination of SdC28 and interferon ex was the only synergistic combination, while SdC28 pius AZT was antagonistic.
Sequence specific effects
While the anti-HIV-1 activity of oligos under certain conditions may be the result of non sequence-specific effects, there have been reports of sequence-specific antisense inhibition. Matsukura et al. (1989) , studied viral growth and HIV-1 protein production in chronically infected H9 cells that had been treated with PS oligos complementary to the initiation region of the rev mRNA. The rev mRNA was chosen as a target because its protein product had been shown to be critical for viral reproduction and for regulation of expression of virion proteins. Furthermore, despite the great instability of the HIV-1 genome, the rev region appears to be highly conserved. The anti-rev 28-mer PS oligo was effective at reducing levels of p24 gag protein production but did not affect cell viability. There were no non sequence-specific results observed with the control oligos, which included the sense oligo, a random oligo, SdC28, and the identical antisense oligo with N 3-methylthymidine residues substituted to prevent Watson-Crick base pairing. The functioning of the rev protein could also be inhibited by oligos. Chin (1992) demonstrated in vitro that the complex formation between rev and the Rev response element (RRE) , an essential association for processing of HIV-1 transcripts, was disrupted by PO oligos complementary to the RRE. These data suggest a potentially interesting cocktail of sequence specific oligo therapeutics, involving the admixture of antisense rev and antisense RRE oligos. In another report (Agrawal et aI., 1989) , a PS oligo was targeted to the intranuclear splice acceptor site at nucleotides 5349-5368 in the HIV genome. It reduced viral gene expression as measured by p17 and p24 production and by reverse transcriptase activity in MOLT 3 cells that had been infected with the virus for 24-48 h. By contrast, a mismatched PS oligo had no inhibitory properties. Previously, oligos complementary to this splice acceptor site and having three or more methylphosphonate (MP) linkages had been tested in a similar system for anti-HIV effects (Sarin et aI., 1988) . A 20-mer with up to five MP linkages was no more effective at inhibiting syncytia formation than the unmodified PO oligo. However, if 18 of the linkages were MP, then potent (98%) inhibition was observed at an oligo concentration of 3 J.LM, with no cellular toxicity.
Other potential targets involving HIV-1 proteins have also been explored. Tat is a regulatory protein, essential for HIV-1 gene expression. The binding of Tat to the trans-activating response element (fAR) of HIV-1 transcripts results in increased viral gene expression. A chimeric oligo with two PS bonds at both termini of a PO sequence complementary to the splice acceptor site of exon 2 ofthe tat gene was an effective anti-HIV compound in HeLA-T4+ cells (Daum et al., 1992) . The functional activity of the oligo was to produce a loss of transactivation, by tat, of a reporter gene under the control of a TAR containing promoter; addition of purified Tat protein overcame the effect of the oligo, thus excluding an oligo-protein interaction. The IC 50 for the chimeric oligo was 2.7 J.Lg mr', vs. 20 J.Lg mr' for an unmodified PO oligo.
An alternative approach was taken by Vickers et al. (1991) , who targeted oligos to the TAR element of HIV-1.ln theory this should effectively block the bin<;ling of the tat protein to TAR. In a reporter gene system with a human placental alkaline phosphatase gene fused to the TAR element and transfected into SK-MEL-2 cells, expression of the alkaline phosphatase gene was found to occur only when a plasmid with the tat gene was cotransfected. PS oligos complementary to TAR prevented alkaline phosphatase expression, but only when they were introduced into the cells via calcium phosphate transfection. In an acute infection assay with CEM cells, PS oligos targeted to TAR were able to inhibit production of RT activity in the culture supernatants. However, the values of IC 50 were no lower than for random PS oligos. In addition, in a chronic infection assay system, the anti-TAR oligos were only slightly more effective at lowering p24 production than the control random oligos.
Similar experiments were performed by Laurence et 8.1. (1991) . In U1.1A cells, MP oligos inhibited expression of a transfected chloramphenicol acetyltransferase (CAT) reporter gene linked to a tat responsive enhancer element. This sequence-specific inhibition was greater than 90% at an oligo concentration of 100 J.LM. While the mechanism of this inhibition was not determined, it was speculated that the oligos were binding to the enhancer region and preventing TAT binding.
The anti-HIV activity of triple helix-forming oligos has also recently been recognized. PO oligos inhibited HlV-1 transcription in infected MT4 and U937 cells by forming triple helices in with the DNA of the viral promoter region (McShan et et., 1992) . Two oligos, a 31-mer and a 38-mer, designed to form triplexes with the transcription initiation site and the Sp1 binding site respectively, seemed to achieve high (6.1 and 4.5 J.LM) intranuclear concentrations within 2 h of addition to the cells. Suppression of viral induced cytopathology and of p24 production were observed, and control oligos were ineffective.
Herpes simplex virus
PS oligos are also inhibitors of Herpes Simplex Virus types 1 and 2. As with HIV, their inhibitory properties are the result of sequence and non sequence-specific effects. Gao et al. (1989) , showed that PS homopolymers were competitive inhibitors of HSV-2 DNA polymerase in vitro. This effect was chain length dependent, with SdC28 the most potent compound (K; = 7 nM). Furthermore, SdC28 was able to competitively inhibit the 3'-5' exonuclease activity of this enzyme (K; = 5 ± 2 nM). A series of PS homopolymers were also used as in vivo inhibitors of HSV-1 (KOS) and HSV-2 (strain 333) replication after infection of Vero or HeLa cells (Gao et al., 1990) . SdC21 , SdC28 and SdT28 (10 J.LM) completely inhibited HSV-2 replication, as judged by plaque formation, when they were added during the 1-h viral adsorption period. No effect was observed if the oligos were added pre or post infection, and there was no effect vs. HSV-1. These data indicate that there may be multiple mechanisms of inhibition; one at the level of DNA polymerase, and another at the stage of viral adsorption and penetration. The authors speculated that the difference in susceptibility between HSV-1 and HSV-2 may be a result of differences at both levels.
Sequence specific antisense results have been demonstrated using a PO oligo complementary to the translation initiation region of the mRNA for the HSV-1 gene Vmw65 (Draper et aI., 1990) . The protein product from this gene is the virion tegument protein and is a transcriptional activating factor. Expression of a plasmid-borne lacZ gene under the control of a promoter responsive to the Vmw65 protein was inhibited in MTX5 cells that had been exposed to 25 fLg ml-1 of antisense oligo for 4 days prior to transfection of the plasmid. The same oligo exhibited a dose dependent antiviral effect in LTK-cells infected at an MOl = 0.5 p.f.u. celr'. Kulka et al. (1989) , achieved sequence specific inhibition of HSV-1 in Vero cells with a methylphosphonate oligo targeted to the acceptor splice junction of HSV-1 immediate early pre-mRNAs 4 and 5. The non-ionic oligo, chosen for increased penetration of mammalian cell membranes, had a single 5' phosphodiester bond to increase solubility. The antiviral activity was observed to be highly sequence specific, with the most effective oligo showing 90-98% viral inhibition at 100 f.LM when added at the time of infection. The inhibitory effect decreased significantly when the sequence was extended beyond the splice acceptor site by as few as one or two bases, or if the oligo was added 1h post infection.~cause an analysis of viral RNA after treatment with th,~~Oligo showed a large species corresponding in size to '~k unspliced transcript, the authors speculated that the antiviral effect of the ollqo was a direct effect of splicing inhibition.
Other viruses
Methylphosphonate oligos, oligo-containing Iiposomes, lipid-conjugated oligos, and poly(L-lysine)-conjugated oligos, have all been studied as anti-vesicular stomatitis virus (VSV) agents. The methylphosphonates, targeted to the initiation codon regions ofthe transcripts for the N, NS, and G proteins of VSV, were effective at preventing viral protein synthesis and at inhibiting virus production in infected L929 cells (Agris et al., 1986) . However, little sequence specificity was observed,. with all oligos blocking synthesis of all viral proteins. Translation of cellular proteins did not appear to be affected, and a polythymidine oligo had no effect, indicating that the results were a result of a specific interaction with viral mRNA. Coupling oligos to a 1,2-di-0-hexadecyl-racglycerol moiety (Shea et aI., 1990) or to poly L-Iysine (Oegolset aI., 1989) led to increased cell association of the oligos, and to more pronounced antisense effects. However, non sequence-specific activity still remained. In a study by Leonetti et al. (1990) , sequence-specific results were apparently obtained when oligos complementary to the VSV N protein mRNA were encapsulated in antibody targeted liposomes. Nonsense and random sequences were ineffective.
A number of other viruses have been the target of in vivo antisense studies. Goodarzi et al. (1990) ,used unmodified PO oligos to inhibit expression of hepatitis B surface antigen in hepatocellular carcinoma cells containing integrated HBV genomes. The most effective oligos were directed to the cap site and translation initiation regions of the mRNA. Final oligo concentrations of 17.4f.LM inhibited as much as 96% of viral gene expression without affecting cellular gene expression, and nonsense oligos were entirely ineffective. The PS oligos tested were 1.5-2 times more effective than the PO oligos for any given sequence and concentration.
Influenzavirus reproduction and viral protein production was successfully prevented in MOCK cells with an oligo linked to an undecyl residue (Kabanov et al., 1990) . The oligo, complementary to an mRNA encoding polymerase 3, was effective at 100 f.LM whereas the unmodified oligo, and the modified nonsense oligo had no effect even at 200f.LM. Birg et al. (1990) , used an octathymidylate oligo coupled to an acridine moiety in blocking SV40 replication in CV-1 cells. It was postulated that this length dependent effect may arise from triple helix formation with the viral DNA and the oligo with intercalation by the acridine group.
Cellular uptake of oligonucleotides
The success of oligos as antisense agents depends on their efficient delivery to the cytoplasm and/or the nucleus. While delivery to appropriate intracellular compartments clearly occurs in some cells (witness the numerous reports of antisense efficacy in cell culture), the poor cellular uptake of oligos has, at least in some cases, been a hinderance to their widespread use. However, little is known about the mechanism of cellular uptake of charged or uncharged oligos.
The published reports on the uptake of charged oligos reveal that there are two components to total cell associated oligo, surface bound and internal (Yakubov et al., 1989; Stein et al., 1993) . Using flow cytometry and confocal microscopy to study uptake of a fluoresceinated PO oligo (FOdT15) in HL60 cells, Stein et al. (1993) , reported saturation binding to the cell surface, with a K m = 22nM. Presumably, this binding is to the 80kOa protein first identified by Loke et al. (1989) and Yakubov et al. (1989) .Competition experiments demonstrated that PS oligos, in general, bound to the cell surface with higher affinities than PO oligos (e.g. K m [SdC28] x 3nM).Thus, at any given time, an accurate measure of internalized FOdT15 could be obtained by competing off the surface bound component with SdC28. The results suggested that the majority of oligo was internalized in a concentration x time-dependent manner, consistent with fluid phase pinocytosis. In HL60 cells there was little or no nuclear accumulation observed by confocal microscopy even up to 24 h.
A fluid-phase/adsorptive endocytic process has also been reported to be responsible for cellular internalization of methylphosphonate oligos, bearing a single, charged phosphodiester group (Shoji et al., 1991) . In Chinese Hamster Ovary tumour cells, the uptake of MP oligos labelled with 32p or rhodamine (TRITe) was temperature dependent, whereas the internalization of free TRITC did not differ between 4°C and 37°C. These data indicated that internalization was due to an active process, and not due to passive diffusion.
Increased oligo internalization may result from modification with poly-L-Iysine (Degols et aI., 1991) , transferrinpolylysine (Citro et aI., 1992) , and by 5' hydrophobic groups (Boutorin et aI., 1989) . 5' Cholesteryl modified oligos have been shown to be internalized at least partially via the LDL receptor (Kreig et et., 1993) , and internalization via adsorptive endocytosis may also be increased. It is not known if cholesteryl-modified oligos are trafficked differently than normal oligos. However, this modification does lead to increased antisense efficacy when the oligos are targeted to the murine MCF-7 endoretroviral env mRNA in splenocytes.
Discussion
There can be little doubt that oligodeoxynucleotides are superb, in vitro, antiviral agents. But how will they fare as in vivo agents? The HIV-1 example may serve us as a paradigm. At present, there is little information in the published literature concerning the pharmacokinetics and pharmacodynamics of PS oligos, although certainly these studies are currently being performed. However, some preliminary data are encouraging (Iversen, 1991) . The plasma concentration of the PS 27-mer anti-rev oligo, as a function of time, fit a two compartment model. The half-time of the shorter phase, which represented transit out ofthe circulation, was about 25 min, while the half-time for total body clearance was 33.9 h. These data suggested that therapeutic tissue concentrations of PS oligo could be maintained for long periods of time with relatively infrequent dosing. However, PS oligos, as do other polyanions, tend to accumulate in the liver, spleen and kidney (Agrawal et al., 1991) . It is unclear if anti-HIV therapeutic activity would be retained in these circumstances. Furthermore, PS oligos appear to undergo chain extension in these organs (Agrawal et al., 1991) . In addition, almost nothing is known about the chronic, as opposed to the acute toxicities, of PS oligos. Due to the ability of PS oligos to bind to a large number of cellular proteins, it is reasonable to assume that such toxicities will exist.
Other important questions also exist. WiII·PS oligos be effectively internalized in chronically infected, non-T cells (e.g. macrophages, glial cells)? What are the effects of HIV-1 strain variability on PS oligo efficacy? Can chronically infected cells escape the effects of sequence-specific oligos? Recent experiments (S. Agrawal, personal communication) indicate that while the virus can escape the non-sequence specific effects of PS oligos, it may not do so for sequence-specific PS oligos. What is the 'ideal' oligo for clinical trials, and has it been synthesized yet? For example, do the increased non-specific effects of PS2 oligos offset their poorer hybridization capabilities? Can less polar oligos, e.g. methylphosphonates, be used for topical applications? Can sufficient quantities of PS oligos be generated at a reasonable cost in a cost-conscious society? And, importantly, how long will it take to determine the answers to these questions?
